cariprazine
Antipsychotic • Brands: VRAYLAR
Last reviewed: 2026-02-12
General information
- Class: Antipsychotic
- Common US brands: VRAYLAR
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
D3/D2 partial agonist (D3‑preferring); 5‑HT1A partial agonist; 5‑HT2A antagonist.
Metabolism & Half‑life
- Metabolism: CYP3A4, CYP2D6
- Half‑life: —
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- VRAYLAR (cariprazine) prescribing information — DailyMed (2025)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology — Pharmacopsychiatry (2018)
- Cariprazine in acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled trial — Schizophrenia Research (2015)
- Cariprazine in acute manic or mixed episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled trial — Bipolar Disorders (2015)
- The CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)